Skip to main content

Efficacy results in seasonal allergies

ZYRTEC® 10 mg provided symptom relief in a 2-week treatment study1*

ZYRTEC® provided relief of seasonal allergic rhinitis symptoms vs placebo1

Mean change from baseline in total symptom severity complex (TSSC) scores in patients with SAR1 

chart 1 Based on main effects models for intent-to-treat population (1)

†Based on main effects models for intent-to-treat population. Week 2 was designated as the primary endpoint. Endpoint = last post-baseline observation. ‡P < 0.01; §P < 0.001.  
Adapted from Noonan, et al.  

The TSSC score includes: 

  • Sneezing 

  • Runny nose 

  • Itchy nose 

  • Itchy eyes 

  • Watery eyes 

  • Post-nasal drip 

Change from baseline to Week 2 in individual SAR symptoms   

ZYRTEC® provided symptom relief from watery eyes as well as relief of sneezing, runny nose, and itchy nose vs placebo1 

  • Multicenter study included 403 patients with SAR, symptoms based on a 4-point scale (0=none to 3=severe) 

  • Significant differences were observed for each individual symptom compromising the TSSC with the exception of nasal congestion at Week 2 

  • Mean change from baseline (with the exception of nasal congestion) to Week 2 showed significantly greater improvement in patients treated with ZYRTEC® compared with patients treated with placebo (P≦0.01). 

Mean reduction from baseline to week 2 in SAR symptom scores1 

chart 2 (1)


॥Based on main effects models on intent-to-treat population. ¶P < 0.001, **P < 0.01, ††P<0.05. 
Adapted from Noonan, et al. 

References 

*Based on a randomized, double-blind, placebo-controlled, parallel-group, multi-centre trial of 403 patients. Patients received either 10 mg ZYRTEC® or placebo for a 2-week treatment period. The TSSC scores were measured by the patient.    

Noonan MJ, Raphael GD, Nayak A, et al. The health-related quality of life effects of once-daily cetirizine HCI in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy. 2003;3(3):351-358 

Clinical Resources
PDF
Zyrtec®